Aptevo regains Nasdaq compliance following $15.9 million equity raise

Published 01/07/2025, 22:20
Aptevo regains Nasdaq compliance following $15.9 million equity raise

Aptevo Therapeutics Inc . (NASDAQ:APVO) announced Tuesday that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2.5 million in stockholders’ equity.

The company received confirmation from the Nasdaq Listing Qualifications Staff after previously disclosing that it was not in compliance for the quarter ended March 31, 2025. According to a statement based on the company’s SEC filing, Aptevo demonstrated compliance by raising approximately $15.9 million in gross proceeds through additional equity capital during the quarter ended June 30, 2025.

As a result, Aptevo reported that it now believes it has stockholders’ equity of at least $2.5 million, meeting the continued listing requirements for The Nasdaq Stock Market LLC.

The information in this article is based on a press release statement included in Aptevo’s Form 8-K filing with the Securities and Exchange Commission.

In other recent news, Aptevo Therapeutics Inc. has successfully closed an $8 million registered direct offering. The biotechnology company sold 2,465,000 shares of common stock or pre-funded warrants, along with warrants to purchase up to 12,325,000 additional shares. Roth Capital Partners (WA:CPAP) served as the placement agent for this transaction. Aptevo plans to use the net proceeds to further its clinical development programs and for general corporate purposes. Additionally, Aptevo has expanded its immuno-oncology pipeline by introducing APVO455, a preclinical bispecific T-cell engager targeting solid tumors. This new therapy joins mipletamig, which has shown an 85% remission rate in frontline acute myeloid leukemia (AML) patients in combination with standard treatments. The company reports that no cytokine release syndrome was observed in the initial cohorts of the ongoing RAINIER trial. Aptevo’s mipletamig has received orphan drug designation for AML, highlighting its potential in treating this aggressive blood cancer.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.